Novo Nordisk's GLP-1 Weight-Loss Pills Spark Price Competition
Originally Published 6 days ago — by Financial Times
Novo Nordisk has announced a price reduction for its Wegovy weight-loss pill in the US to compete with Eli Lilly's market offerings, initiating a price war in the weight-loss drug industry. The company will offer lower doses at significantly reduced prices, aiming to attract more overweight and obese patients, especially following the recent FDA approval of an oral version of Wegovy. This move comes amid a competitive landscape with Lilly's upcoming drug, orforglipron, expected to be approved soon.
